The World Liquid Biopsy Industry is Projected to Reach at a CAGR of ~ 28 % - Forecast to 2022

Biopsy involves extracting a sample of tissue and testing it for the presence of diseases especially cancer. Traditional tissue biopsy is a painful technique and also has a high rate of false results. Moreover the technique is costly, time consuming and not applicable for extracting samples such as those close to vital organs such as heart. Liquid biopsy overcomes these problems of tissue biopsy by using biomarkers present in samples such as blood, urine etc. and thus is a comparatively non-invasive technique. Liquid biopsy also provides greater information about the sample which is real time. The real time data can be used for monitoring and thereby determining the treatment for diseases such as cancer. The greater sensitivity of tissue biopsy coupled with the development of sophisticated detectors with extremely low detection rates have enabled the early detection of diseases which is the holy grail of cancer.
Other market drivers for the liquid biopsy market are rising rates of cancer, growing investment in research and development, collaborations between companies and public organizations, rise in geriatric population, rising expenditure on health etc. The factors which are inhibiting the growth of the market includes the prohibitive costs associated with liquid biopsy and the differential awareness and availability between developing and the developed world. However, not all cancer patients benefit from early detection as some cancer types such as brain cancer and prostate cancer may lie dormant for many years. Further liquid biopsy is not all non-invasive as can be seen in case of using spinal fluid as sample.
Major Players of Global liquid biopsy market:
The major participants of this market are: Guardant Health, Inc., Trovagene, Inc., RainDance Technologies, Inc., Agena Bioscience Inc. Inc., Admera Health, Biocept, Inc., Circulogene Theranostics, Inivata Ltd., SAGA Diagnostics AB, Exosome Diagnostics and others.

Sample Report Available at https://www.marketresearchfuture.com/sample_request/710 .
Key findings
• Circulating tumor cells (CTCs) segment dominates both in terms of market share as well as revenues, contributing approx. 55.48% of the revenue share of the liquid biopsy market.
• On the basis of the therapeutic application, the segment for Cancer will reflect the highest growth potential, with over 82.83% of the market share by revenues. However, the urine sample segment is anticipated to witness noticeable growth.
• The market for liquid biopsy is dominated by North America and Europe and this trend will continue. Asia-Pacific market is the fastest growing market and is expected to grow at a CAGR of 29.7% during forecasted period

Segments:
Global Liquid Biopsy market has been segmented on the basis of biomarker type which comprises of circulating tumor cells (Ctcs), circulating tumor DNA (Ctdna), extracellular vesicles (Evs) and other biomarker. On the basis of application; market is segmented into cancer therapeutic application, reproductive health, and other therapeutic application. On the basis of sample; market is segmented into blood, urine and others. On the basis of end-users; market is segmented into hospitals and laboratories, academic and research centers and others.

Regional Analysis of Global Liquid Biopsy market:
Globally North America is the largest market for Global Liquid Biopsy market. Europe is the second-largest market for Global Liquid Biopsy market. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future. North America accounted for the largest market share of 37.95% in 2016 accounting for a market value of 1,499.10 million in 2016. Asia pacific is the fastest growing market which is growing at a CAGR of 28.8%.

Browse complete report at https://www.marketresearchfuture.com/reports/liquid-biopsy-market-710 .
List of Table
TABLE 1 GLOBAL LIQUID BIOPSY MARKET BY BIOMARKER TYPE, $ MILLION (2016-2022) 34
TABLE 2 CIRCULATING TUMOR CELLS (CTCS) MARKET, BY REGION, 2014-2022 ($ MILLION) 36
TABLE 3 CIRCULATING TUMOUR DNA (CTDNA) MARKET, BY REGION, 2014-2022 ($ MILLION) 38
TABLE 4 EXTRACELLULAR VESICLES (EVS) MARKET, BY REGION, 2014-2022 ($ MILLION) 39
TABLE 5 OTHER BIOMARKER TYPE MARKET, BY REGION, 2014-2022 ($ MILLION) 40
TABLE 6 GLOBAL LIQUID BIOPSY MARKET BY THERAPEUTIC APPLICATIONS, 2014-2022 ($ MILLION) 42
TABLE 7 CANCER THERAPEUTIC APPLICATION MARKET, BY REGION, 2014-2022 ($ MILLION) 43
TABLE 8 REPRODUCTIVE HEALTH THERAPEUTIC APPLICATION MARKET, BY REGION, 2014-2022 ($ ILLION) 44
TABLE 9 OTHER THERAPEUTIC APPLICATION MARKET, BY REGION, 2014-2022 ($ MILLION) 45
TABLE 10 GLOBAL LIQUID BIOPSY MARKET BY SAMPLE, 2014-2022 ($ MILLION) 47
TABLE 11 BLOOD SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 49
TABLE 12 URINE SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 50
TABLE 13 OTHER SAMPLE MARKET, BY REGION, 2014-2022 ($ MILLION) 51
TABLE 14 GLOBAL LIQUID BIOPSY MARKET BY END USER, 2014-2022 ($ MILLION) 52

About us
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact:
Market Research Future
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: salesteam@Marketresearchfuture.Com

This release was published on openPR.